KalVista Pharmaceuticals(KALV) - 2026 Q2 - Quarterly Results

Financial Performance - EKTERLY® generated $13.7 million in net product revenue for the third quarter ended September 30, 2025[1]. - The company reported a net loss of $49.5 million for the three months ended September 30, 2025, compared to a net loss of $39.1 million in the same period of 2024[16]. - Research and development expenses decreased to $12.0 million from $18.7 million year-over-year, primarily due to reduced clinical trial expenses[16]. - Selling, general and administrative expenses increased to $46.5 million from $24.8 million year-over-year, driven by commercialization expenses related to EKTERLY[16]. - As of September 30, 2025, the company had approximately $309.2 million in cash, cash equivalents, and marketable securities, expected to fund operations through profitability[8]. Product Adoption and Market Expansion - 937 patient start forms were received in the US, indicating strong adoption as the first and only oral on-demand treatment for hereditary angioedema (HAE)[4]. - EKTERLY was launched in Germany in October 2025, with initial orders indicating encouraging demand[3]. - The company received regulatory approvals for EKTERLY in the US, EU, UK, Switzerland, and Australia, expanding its market reach[4]. - The company anticipates continued growth in patient starts and repeat prescriptions for EKTERLY, reflecting confidence in its clinical value[3]. Funding and Strategic Initiatives - The company successfully closed a $144 million convertible note offering to support its global launch strategy[3].